Lenalidomide
Other Immunosuppressants
Sold as REVLIMID · LENALIDOMDE JRLTD
- Drug class
- Other Immunosuppressants
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 214
Overview
Lenalidomide is an active pharmaceutical ingredient in the Other Immunosuppressants group (L04AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 160 | May 22, 2026 |
| CA Canada | Health Canada | 49 | July 24, 2025 |
| EU European Union | EMA | 5 | May 11, 2026 |
GBUnited Kingdom· MHRA
160 products
Uses
Multiple myeloma Lenalidomide as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. 2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromes Lenalidomide as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Follicular lymphoma Lenalidomide in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).
CACanada· Health Canada
49 products
Uses
• REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion- dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated (see 4 CLINICAL TRIALS, Myelodysplastic Syndromes) • REVLIMID® in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who are not eligible for stem cell transplant.
Limitation of Use: • REVLIMID® is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (see 7 WARNINGS AND PRECAUTIONS, Increased Mortality in Patients with CLL).
Distribution restrictions:
EUEuropean Union· EMA
5 products
Uses
Multiple myeloma Lenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. 2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromes Lenalidomide Mylan as monotherapy is indicated for the treatment of adult patients with transfusion- dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
1). Follicular lymphoma Lenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).
Drug interactions
Known interactions involving Lenalidomide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 299. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL494450140 · revised February 20, 2026
- [2]Health Canada (DPD) · 02304899 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/005306 · revised May 11, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.